Lobeglitazone/sitagliptin - Chong Kun Dang
Alternative Names: CKD-396; Sitagliptin/lobeglitazone - Chong Kun DangLatest Information Update: 03 Jun 2021
At a glance
- Originator Chong Kun Dang
- Class Amines; Antihyperglycaemics; Fluorinated hydrocarbons; Pyrazines; Pyrimidines; Small molecules; Thiazolidinediones; Triazoles
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors; Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor gamma agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Type 2 diabetes mellitus
Most Recent Events
- 01 Jun 2021 Phase-III clinical trials in Type 2 diabetes mellitus in South Korea (PO) (Chong Kun Dang Pharmaceutical pipeline, June 2021)
- 26 Feb 2020 Chemical structure information added
- 24 Feb 2020 Phase-I clinical trials in Type 2 diabetes mellitus (In volunteers) in South Korea, before May 2020 (PO) (Chong Kun Dang pipeline, May 2020)